Skip to main content
Clinical Trials/NCT02940444
NCT02940444
Unknown
Phase 1

Safety and Efficacy of Preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery

West China Hospital1 site in 1 country2,000 target enrollmentJune 2016

Overview

Phase
Phase 1
Intervention
Heparin
Conditions
Thromboprophylaxis
Sponsor
West China Hospital
Enrollment
2000
Locations
1
Primary Endpoint
INR
Last Updated
9 years ago

Overview

Brief Summary

Thromboembolism is an important perioperative complication in major thoracic surgery, even though current guidelines have recommended postoperative administration of heparin or LMWH for thromboprophylaxis for those high-risk patients, there are still many cases of thromboembolism. Therefore, as the guideline itself writes, the investigators believe the rational of dose and timing of heparin in thoracic surgery are still not well established. Therefore, the investigators aimed to conduct this randomized controlled study to explore the safety and efficacy of preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery.

Registry
clinicaltrials.gov
Start Date
June 2016
End Date
June 2018
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Yi-Dan Lin

proffessor

West China Hospital

Eligibility Criteria

Inclusion Criteria

  • 18-75 years old without any preoperative VTEs;
  • patients undergoing major thoracic surgery (including lobectomy, esophagectomy, and thymectomy).

Exclusion Criteria

  • patients with coagulation disorders: preoperative international normalized ratio (INR) \> 1.5, or blood platelet count \< 50x10\^9/L;
  • patients receiving any therapeutic anticoagulation preoperatively;
  • patients with severe renal or liver dysfunction.

Arms & Interventions

case group

start heparin sodium (5000IU, BID) upon admission, and continue until discharge

Intervention: Heparin

control group

start heparin sodium (5000 IU,BID) from postoperative day 1, and continue until discharge

Intervention: Heparin

Outcomes

Primary Outcomes

INR

Time Frame: on postoperative day 1 for both group

blood platlet count(/L)

Time Frame: on postoperative day 1 for both group

chest tube drainage volume (ml)

Time Frame: from postoperative day 1 to chest tube remove(usually on postoperative day 3 for lobectomy or thymectomy,on postoperative day 7 for esophagectomy )

APTT (s)

Time Frame: on postoperative day 1 for both group

intraoperative bleeding volume (ml)

Time Frame: the bleeding volume (ml) during operation in the operation room for all patients

During the operation, the blood loss of each patient was collected and measured, and recorded by the investigators.

PT(s)

Time Frame: on postoperative day 1 for both group

thromboembolism occurence rate (%)

Time Frame: within 30 days after surgery

chest tube drainage duration (days)

Time Frame: from postoperative day 1 to chest tube remove(usually on postoperative day 3 for lobectomy or thymectomy,on postoperative day 7 for esophagectomy )

Secondary Outcomes

  • PT(s)(rightly upon hospital admission day)
  • APTT(s)(rightly upon hospital admission day)
  • INR(rightly upon hospital admission day)
  • blood platlet count(/L)(rightly upon hospital admission day)

Study Sites (1)

Loading locations...

Similar Trials